A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Ac

• Status: RECRUITING
• Trial end date: 2027-06-30

Summary

This study aimed to compare the efficacy and safety of a precision treatment regimen based on clinical-molecular phenotypes with a conventional treatment regimen in the treatment of patients with active Takayasu's arteritis based on a randomized, controlled, open-label, multicenter study.

• Phase: PHASE4

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Adalimumab; Glucocorticoids; Methotrexate; Prednisone; tocilizumab; tofacitinib